Previous 10 | Next 10 |
Ligand Pharmaceuticals (LGND): Q4 Non-GAAP EPS of $1.62 beats by $0.63; GAAP EPS of $0.35 misses by $0.05.Revenue of $70M (+159.3% Y/Y) beats by $16.06M.FY2021 guidance: Ligand now expects total revenues to be approximately $291 million vs. $288.39M and adjusted diluted EPS to be approximatel...
Raises 2021 Financial Guidance Conference Call Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and pr...
Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q4 earnings results on Wednesday, February 3rd, before market open.The consensus EPS Estimate is $0.99 (+39.4% Y/Y) and the consensus Revenue Estimate is $53.94M.Over the last 2 years, LGND has beaten EPS estimates 100% of the time...
Ligand Pharma ([[LGND]] -5.4%) and partner Travere Therapeutics ([[TVTX]] +14.0%) announces that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis ((FSGS)) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint ((FPRE)) a...
[[ABBV]], [[APO]], [[APTV]], [[AVY]], [[BIIB]], [[BIP]], [[BSX]], [[CHKP]], [[CNHI]], [[CPRI]], [[DT]], [[EPD]], [[EVR]], [[GWW]], [[HUM]], [[HWM]], [[INGR]], [[LAD]], [[LGND]], [[MIME]], [[MSGS]], [[MTOR]], [[PFGC]], [[SC]], [[SLAB]], [[SMG]], [[SNDR]], [[SPOT]], [[TGI]], [[VNE]], [[WNC]]For...
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan Liga...
The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks. These stocks may be looking at a short squeeze soon. For further details see: Gamestopping Biopharma: These Three Stocks...
LGND helps other biotech/pharmaceutical companies discover, develop and manufacture drugs. LGND's OmniAb technology sees widespread industry use and two antibodies discovered using the technology are close to potential regulatory approval in 2021. LGND is one of the most shorted b...
A lot of comparisons are made regarding the current speculation in the equity market to what occurred in the late 1990s and early 2000s. While the GameStops, SPACs, and Teslas garner the most attention, the equity market bubble today is actually far more encompassing, even across the ...
Insider buying at Ligand Pharmaceuticals (LGND) has accelerated in 2021, the latest SEC filings submitted by the company indicate.Ligand Pharma CEO John Higgins, and COO, Matthew Foehr have purchased a net ~38.1K and ~5.2K of company shares for the year so far.The duo ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...